Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
20 hedge funds and large institutions have $4.77M invested in Telesis Bio, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 6 closing their positions.
6% more capital invested
Capital invested by funds: $4.5M → $4.77M (+$267K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 24 → 20 (-4)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$17.7K |
| 2 |
DDC
DF Dent & Co
Baltimore,
Maryland
|
+$8.34K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.29K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$165 |
| 5 |
JP Morgan Chase
New York
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Penbrook Management
New York
|
-$141K |
| 2 |
Millennium Management
New York
|
-$27.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$15K |
| 4 |
Renaissance Technologies
New York
|
-$11K |
| 5 |
MAM
McCarthy Asset Management
Redwood Shores,
California
|
-$4.39K |
TBIO Hedge Fund Activity: Q1 2024 in Review
20 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q1 2024, worth a combined $4.77M — up 5.9% from $4.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TBIO and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, adding an estimated $17.7K. The largest seller was Penbrook Management, exiting entirely with an estimated $141K sold.
- 20 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q1 2024, down from 24 in Q4 2023.
- Funds reported $4.77M of Telesis Bio, Inc. Common Stock stock for Q1 2024, up 5.9% quarter-over-quarter.
- 2 funds opened new Telesis Bio, Inc. Common Stock positions in Q1 2024 and 6 closed out, a net change of -4 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q1 2024 was UBS Group, an estimated $17.7K added.
- The largest Telesis Bio, Inc. Common Stock seller in Q1 2024 was Penbrook Management, an estimated $141K sold.
Based on aggregated 13F filings for Q1 2024.